Advanced Prostate Cancer
J. Brantley Thrasher, MD, highlighted several studies to watch out for in the area of advanced prostate cancer, including:
- a paper assessing adherence to international guidelines of androgen deprivation therapy with external beam radiation therapy
- a presentation on the role of salvage extended lymph node dissection in patients with rising PSA and positron emission tomography/computed tomography scan-detected nodal recurrence of prostate cancer
- research on novel P13K/p110beta-specific inhibitors that eliminate enzalutamide (XTANDI) resistance.
“One major theme this year is new compounds either added to other treatments or tested alone in metastatic castration-resistant prostate cancer (mCRPC) patients. Another major theme is the use of circulating tumor cells as serum biomarkers in mCRPC,” commented Dr. Thrasher, professor and chair of urology at the University of Kansas Medical Center, Kansas City.
Specifically, here are the AUA 2016 abstracts Dr. Thrasher said to watch for:
PD28-07: Assessment of the rate of adherence to international guidelines of androgen deprivation therapy with external beam radiation therapy- a population-based study
PD28-02: An iPod-Guided Slow Breathing Intervention to Control Hot Flashes in Advanced Prostate Cancer Patients on Hormone Therapy
MP50-02: Does The Number Of Lymph Nodes Sampled During Radical Prostatectomy Impact Risk of Biochemical Recurrence in Patients With Seminal Vesicle Invasion?
Ketan K. Badani
MP50-08: Can Angiotensin-Converting Enzyme Inhibitors Reduce the Incidence, Severity, and Duration of Radiation Proctitis?
MP50-11: The role of salvage extended lymph node dissection (LND) in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer
Dr. Thrasher also pointed to these abstracts from Prostate Cancer: Advanced (Including Drug Therapy) III:
PD32-02: Novel PI3K/p110beta-Specific Inhibitors Eliminate Enzalutamide Resistance in Prostate Cancer
PD32-06: Long-term safety and antitumor activity of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients from the ARADES and the ARAFOR trials
PD32-09: Combination effect of therapies targeting the PI3K-mTOR and AR signaling pathways in prostate cancer
PD32-11: Gene Expression Analysis of Bone Metastasis and Circulating Tumor Cells from Metastatic Castrate-resistant Prostate Cancer Patients
PD32-12: LONG-TERM FOLLOW-UP OF CIRCULATING TUMOR CELLS AS PREDICTORS FOR SURVIVAL IN MEN TREATED WITH ABIRATERONE ACETATE FOR CASTRATION RESISTANT PROSTATE CANCER FOLLOWING CHEMOTHERAPY